The creator of the first FDA-authorised prescription video game for ADHD — went public at $1B+ via SPAC, then sold to Virtual Therapeutics for $34M a year later
Evaluating only Akili Interactive’s profile at its peak — without knowing the outcome — the model ranked Unit economics as the #1 likely cause. Documented cause: Market collapse.
Akili Interactive built EndeavorRx, a prescription video game for children with ADHD that was authorised by the FDA in June 2020 — the first prescription digital therapeutic to receive FDA clearance as a game. The product was genuinely innovative. The company raised $110M+ in private capital and went public via SPAC merger in August 2022 at an implied valuation of over $1B. But the commercial launch exposed fundamental market barriers: physicians were reluctant to prescribe a video game; insurance coverage for digital therapeutics was inconsistent; and parents often chose medication over a game-based intervention. Akili's revenue remained well below what was needed to justify its public valuation. The stock collapsed from ~$10 to under $0.50. In August 2023, Akili was acquired by Virtual Therapeutics for approximately $34M — a 97% discount to its SPAC valuation.
Alternative account: Akili built EndeavorRx, the first FDA-authorized prescription video game for ADHD in children. Went public via SPAC in 2022. Commercial adoption was catastrophically slow: physicians did not prescribe it, payers did not cover it, and parents were not willing to pay out-of-pocket for a video game prescription. The company sold itself to Endeavor BioMedicines for $34M in July 2023 — far below the $110M raised.
Lesson
“Digital therapeutics require reimbursement pathways before commercial launch, not after. The pathway to prescriber adoption takes longer than the pathway to FDA clearance.
Alternative account: Digital therapeutics require a simultaneous three-sided market creation: physician prescribing behavior, payer coverage, and patient out-of-pocket willingness. No FDA approval creates any of these automatically.”